USAResearch and clinical trials
Oral gildeuretinol in Stargardt disease: growth of retinal damage slowed slightly in a two-year study
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
A two-year, placebo-controlled study was carried out at 7 centers in the USA. 50 patients received oral gildeuretinol or placebo. The results were also compared with natural history data from 54 patients. The growth rate of the damaged area was 15–22% slower in the drug group. No serious side effects were seen, but an effect on vision was not shown in this study.
What does it mean for patients and families?
There is no approved drug for Stargardt disease yet; this small study is a first step. Its effect on vision must be tested in larger studies. The drug is not in use in Türkiye.
Source
Scientific paper: Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial. JAMA Ophthalmology, 2026. DOI: 10.1001/jamaophthalmol.2026.3662 · PubMed 42690655
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Stargardt disease
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.